View the agenda (as pdf).
Keynote: How Can the Genetic Architecture of AD Inform Disease Mechanism?
Julie Williams, B.Sc., Ph.D.
Polygenic Risk Scores for AD: Applications and Optimization for Diverse Populations
Giuseppe Tosto, M.D., Ph.D.
The Epidemiology and Genetics of AD in Africa
Rufus Akinyemi, M.B.B.S., M.Sc., Ph.D., M.W.A.C.P., F.M.C.P.
Vascular Risk Factors and Cognitive Decline in Diverse Populations
Ralph Sacco, M.D, M.S., F.A.H.A., F.A.A.N.
Imaging and Blood Biomarkers in the Colombian Kindred with Autosomal Dominant AD
Yakeel Quiroz-Gaviria, Ph.D.
Keynote: Multi-Scale Data Integration to Transition Genetic Associations to Therapeutics
Phil De Jager, M.D., Ph.D.
Genetic Counseling and Testing for Alzheimer’s Disease: A View from the Trenches
Robin Bennett, M.S., C.G.C., Ph.D.
From Gene Discovery to Clinical Translation: Ethical and Social Implications
Stephanie Malia Fullerton, D.Phil.
Keynote: Using Genomics to Identify Therapeutic Targets for Non-Alzheimer’s Dementias
Brian Traynor, M.D., Ph.D.
Omics Analysis to Small Molecule Drug Development: RAB10 and NEK7
John “Keoni” S.K. Kauwe III, Ph.D.
Artificial Intelligence Approaches for Discovery in Alzheimer’s Disease Biobanks
Paul Thompson, Ph.D.